skip to main content
Language:
Search Limited to: Search Limited to: Resource type Show Results with: Show Results with: Search type Index

Results 1 - 20 of 28,996  for All Library Resources

Results 1 2 3 4 5 next page
Refined by: subject: Diabetes remove subject: Risk Factors remove
Result Number Material Type Add to My Shelf Action Record Details and Options
1
Epidemiology of cardiovascular disease in China: current features and implications
Material Type:
Article
Add to My Research

Epidemiology of cardiovascular disease in China: current features and implications

Nature reviews cardiology, 2019-04, Vol.16 (4), p.203-212 [Peer Reviewed Journal]

COPYRIGHT 2019 Nature Publishing Group ;Copyright Nature Publishing Group Apr 2019 ;ISSN: 1759-5002 ;EISSN: 1759-5010 ;DOI: 10.1038/s41569-018-0119-4 ;PMID: 30467329

Full text available

2
Role of Gut Microbiota-Generated Short-Chain Fatty Acids in Metabolic and Cardiovascular Health
Material Type:
Article
Add to My Research

Role of Gut Microbiota-Generated Short-Chain Fatty Acids in Metabolic and Cardiovascular Health

Current nutrition reports, 2018-12, Vol.7 (4), p.198-206 [Peer Reviewed Journal]

The Author(s) 2018 ;EISSN: 2161-3311 ;DOI: 10.1007/s13668-018-0248-8 ;PMID: 30264354

Digital Resources/Online E-Resources

3
Effects of n−3 Fatty Acid Supplements in Diabetes Mellitus
Material Type:
Article
Add to My Research

Effects of n−3 Fatty Acid Supplements in Diabetes Mellitus

The New England journal of medicine, 2018-10, Vol.379 (16), p.1540-1550 [Peer Reviewed Journal]

Copyright © 2018 Massachusetts Medical Society. All rights reserved. ;ISSN: 0028-4793 ;EISSN: 1533-4406 ;DOI: 10.1056/NEJMoa1804989 ;PMID: 30146932

Full text available

4
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Material Type:
Article
Add to My Research

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes

The New England journal of medicine, 2015-11, Vol.373 (22), p.2117-2128 [Peer Reviewed Journal]

Copyright © 2015 Massachusetts Medical Society. All rights reserved. ;ISSN: 0028-4793 ;EISSN: 1533-4406 ;DOI: 10.1056/NEJMoa1504720 ;PMID: 26378978

Full text available

5
How Does Empagliflozin Reduce Cardiovascular Mortality? Insights From a Mediation Analysis of the EMPA-REG OUTCOME Trial
Material Type:
Article
Add to My Research

How Does Empagliflozin Reduce Cardiovascular Mortality? Insights From a Mediation Analysis of the EMPA-REG OUTCOME Trial

Diabetes care, 2018-02, Vol.41 (2), p.356-363 [Peer Reviewed Journal]

2017 by the American Diabetes Association. ;Copyright American Diabetes Association Feb 1, 2018 ;ISSN: 0149-5992 ;EISSN: 1935-5548 ;DOI: 10.2337/dc17-1096 ;PMID: 29203583

Full text available

6
Aortic Pulse Wave Velocity Improves Cardiovascular Event Prediction: An Individual Participant Meta-Analysis of Prospective Observational Data From 17,635 Subjects
Material Type:
Article
Add to My Research

Aortic Pulse Wave Velocity Improves Cardiovascular Event Prediction: An Individual Participant Meta-Analysis of Prospective Observational Data From 17,635 Subjects

Journal of the American College of Cardiology, 2014-02, Vol.63 (7), p.636-646 [Peer Reviewed Journal]

2015 INIST-CNRS ;Copyright © 2014 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved. ;Copyright Elsevier Limited Feb 25, 2014 ;ISSN: 0735-1097 ;EISSN: 1558-3597 ;DOI: 10.1016/j.jacc.2013.09.063 ;PMID: 24239664 ;CODEN: JACCDI

Full text available

7
CAPTURE: a multinational, cross-sectional study of cardiovascular disease prevalence in adults with type 2 diabetes across 13 countries
Material Type:
Article
Add to My Research

CAPTURE: a multinational, cross-sectional study of cardiovascular disease prevalence in adults with type 2 diabetes across 13 countries

Cardiovascular diabetology, 2021-07, Vol.20 (1), p.154-154, Article 154 [Peer Reviewed Journal]

2021. The Author(s). ;2021. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;Attribution ;The Author(s) 2021 ;ISSN: 1475-2840 ;EISSN: 1475-2840 ;DOI: 10.1186/s12933-021-01344-0 ;PMID: 34315481

Full text available

8
Intensive Diabetes Treatment and Cardiovascular Outcomes in Type 1 Diabetes: The DCCT/EDIC Study 30-Year Follow-up
Material Type:
Article
Add to My Research

Intensive Diabetes Treatment and Cardiovascular Outcomes in Type 1 Diabetes: The DCCT/EDIC Study 30-Year Follow-up

Diabetes care, 2016-05, Vol.39 (5), p.686-693 [Peer Reviewed Journal]

2016 by the American Diabetes Association. Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. ;Copyright American Diabetes Association May 2016 ;2016 by the American Diabetes Association. Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. 2016 ;ISSN: 0149-5992 ;EISSN: 1935-5548 ;DOI: 10.2337/dc15-1990 ;PMID: 26861924 ;CODEN: DICAD2

Full text available

9
Predicting timing of clinical outcomes in patients with chronic kidney disease and severely decreased glomerular filtration rate
Material Type:
Article
Add to My Research

Predicting timing of clinical outcomes in patients with chronic kidney disease and severely decreased glomerular filtration rate

Kidney international, 2018-06, Vol.93 (6), p.1442-1451 [Peer Reviewed Journal]

2018 International Society of Nephrology ;Copyright © 2018 International Society of Nephrology. Published by Elsevier Inc. All rights reserved. ;Copyright Elsevier Limited Jun 2018 ;ISSN: 0085-2538 ;ISSN: 1523-1755 ;EISSN: 1523-1755 ;DOI: 10.1016/j.kint.2018.01.009 ;PMID: 29605094

Full text available

10
Intensive Glucose Control in Patients with Type 2 Diabetes — 15-Year Follow-up
Material Type:
Article
Add to My Research

Intensive Glucose Control in Patients with Type 2 Diabetes — 15-Year Follow-up

The New England journal of medicine, 2019-06, Vol.380 (23), p.2215-2224 [Peer Reviewed Journal]

Copyright © 2019 Massachusetts Medical Society. All rights reserved. ;Copyright © 2019 Massachusetts Medical Society. ;ISSN: 0028-4793 ;EISSN: 1533-4406 ;DOI: 10.1056/NEJMoa1806802 ;PMID: 31167051

Full text available

11
Cardiovascular Effects of Intensive Lifestyle Intervention in Type 2 Diabetes
Material Type:
Article
Add to My Research

Cardiovascular Effects of Intensive Lifestyle Intervention in Type 2 Diabetes

The New England journal of medicine, 2013-07, Vol.369 (2), p.145-154 [Peer Reviewed Journal]

Copyright © 2013 Massachusetts Medical Society. All rights reserved. ;2014 INIST-CNRS ;ISSN: 0028-4793 ;EISSN: 1533-4406 ;DOI: 10.1056/NEJMoa1212914 ;PMID: 23796131 ;CODEN: NEJMAG

Full text available

12
Dapagliflozin is associated with lower risk of cardiovascular events and all-cause mortality in people with type 2 diabetes (CVD-REAL Nordic) when compared with dipeptidyl peptidase-4 inhibitor therapy: A multinational observational study
Material Type:
Article
Add to My Research

Dapagliflozin is associated with lower risk of cardiovascular events and all-cause mortality in people with type 2 diabetes (CVD-REAL Nordic) when compared with dipeptidyl peptidase-4 inhibitor therapy: A multinational observational study

Diabetes, obesity & metabolism, 2018-02, Vol.20 (2), p.344

2017 The Authors. Diabetes, Obesity and Metabolism published by John Wiley & Sons Ltd. ;ISSN: 1463-1326 ;EISSN: 1463-1326 ;DOI: 10.1111/dom.13077 ;PMID: 28771923

Digital Resources/Online E-Resources

13
Impact of Excessive Weight Gain on Cardiovascular Outcomes in Type 1 Diabetes: Results From the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study
Material Type:
Article
Add to My Research

Impact of Excessive Weight Gain on Cardiovascular Outcomes in Type 1 Diabetes: Results From the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study

Diabetes care, 2017-12, Vol.40 (12), p.1756-1762 [Peer Reviewed Journal]

2017 by the American Diabetes Association. ;Copyright American Diabetes Association Dec 2017 ;2017 by the American Diabetes Association. 2017 ;ISSN: 0149-5992 ;EISSN: 1935-5548 ;DOI: 10.2337/dc16-2523 ;PMID: 29138273

Full text available

14
Follow-up of Glycemic Control and Cardiovascular Outcomes in Type 2 Diabetes
Material Type:
Article
Add to My Research

Follow-up of Glycemic Control and Cardiovascular Outcomes in Type 2 Diabetes

The New England journal of medicine, 2015-06, Vol.372 (23), p.2197-2206 [Peer Reviewed Journal]

Copyright © 2015 Massachusetts Medical Society. All rights reserved. ;ISSN: 0028-4793 ;EISSN: 1533-4406 ;DOI: 10.1056/NEJMoa1414266 ;PMID: 26039600

Full text available

15
Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes
Material Type:
Article
Add to My Research

Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes

The New England journal of medicine, 2021-12, Vol.385 (24), p.2252-2263 [Peer Reviewed Journal]

Copyright © 2021 Massachusetts Medical Society. All rights reserved. ;Copyright © 2021 Massachusetts Medical Society. ;COPYRIGHT 2021 Massachusetts Medical Society ;ISSN: 0028-4793 ;EISSN: 1533-4406 ;DOI: 10.1056/NEJMoa2110956 ;PMID: 34449181

Full text available

16
Design and baseline characteristics of participants in the Researching cardiovascular Events with a Weekly INcretin in Diabetes (REWIND) trial on the cardiovascular effects of dulaglutide
Material Type:
Article
Add to My Research

Design and baseline characteristics of participants in the Researching cardiovascular Events with a Weekly INcretin in Diabetes (REWIND) trial on the cardiovascular effects of dulaglutide

Diabetes, obesity & metabolism, 2018-01, Vol.20 (1), p.42

2017 John Wiley & Sons Ltd. ;ISSN: 1463-1326 ;EISSN: 1463-1326 ;DOI: 10.1111/dom.13028 ;PMID: 28573765

Digital Resources/Online E-Resources

17
Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial
Material Type:
Article
Add to My Research

Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial

The Lancet (British edition), 2019-07, Vol.394 (10193), p.121-130 [Peer Reviewed Journal]

2019 Elsevier Ltd ;Copyright © 2019 Elsevier Ltd. All rights reserved. ;2019. Elsevier Ltd ;ISSN: 0140-6736 ;ISSN: 1474-547X ;EISSN: 1474-547X ;DOI: 10.1016/S0140-6736(19)31149-3 ;PMID: 31189511

Full text available

18
Dietary Flavonoids: Cardioprotective Potential with Antioxidant Effects and Their Pharmacokinetic, Toxicological and Therapeutic Concerns
Material Type:
Article
Add to My Research

Dietary Flavonoids: Cardioprotective Potential with Antioxidant Effects and Their Pharmacokinetic, Toxicological and Therapeutic Concerns

Molecules (Basel, Switzerland), 2021-06, Vol.26 (13), p.4021 [Peer Reviewed Journal]

2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;2021 by the authors. 2021 ;ISSN: 1420-3049 ;EISSN: 1420-3049 ;DOI: 10.3390/molecules26134021 ;PMID: 34209338

Full text available

19
Management of Cardiovascular Disease During Coronavirus Disease (COVID-19) Pandemic
Material Type:
Article
Add to My Research

Management of Cardiovascular Disease During Coronavirus Disease (COVID-19) Pandemic

Trends in cardiovascular medicine, 2020-08, Vol.30 (6), p.315 [Peer Reviewed Journal]

Copyright © 2020. Published by Elsevier Inc. ;Copyright Elsevier Limited Aug 2020 ;ISSN: 1050-1738 ;EISSN: 1873-2615 ;DOI: 10.1016/j.tcm.2020.05.004 ;PMID: 32474135

Digital Resources/Online E-Resources

20
Economic Burden of Cardiovascular Disease in Type 2 Diabetes: A Systematic Review
Material Type:
Article
Add to My Research

Economic Burden of Cardiovascular Disease in Type 2 Diabetes: A Systematic Review

Value in health, 2018-07, Vol.21 (7), p.881 [Peer Reviewed Journal]

Copyright © 2018 International Society for Pharmacoeconomics and Outcomes Research (ISPOR). Published by Elsevier Inc. All rights reserved. ;EISSN: 1524-4733 ;DOI: 10.1016/j.jval.2017.12.019 ;PMID: 30005761

Digital Resources/Online E-Resources

Results 1 - 20 of 28,996  for All Library Resources

Results 1 2 3 4 5 next page

Personalize your results

  1. Edit

Refine Search Results

Expand My Results

  1.   

Refine My Results

Creation Date 

From To
  1. Before 1989  (13)
  2. 1989 To 1996  (126)
  3. 1997 To 2004  (972)
  4. 2005 To 2013  (5,793)
  5. After 2013  (22,108)
  6. More options open sub menu

Subject 

  1. Science & Technology  (23,495)
  2. Cardiovascular Disease  (22,291)
  3. Life Sciences & Biomedicine  (20,764)
  4. Humans  (17,725)
  5. Hypertension  (13,379)
  6. Female  (11,726)
  7. Male  (11,621)
  8. Cardiovascular Diseases  (11,483)
  9. Middle Aged  (9,746)
  10. Blood Pressure  (9,071)
  11. Mortality  (8,913)
  12. Diabetes Mellitus  (8,688)
  13. Aged  (7,991)
  14. Cholesterol  (6,924)
  15. Body Mass Index  (6,817)
  16. Patients  (6,778)
  17. Adult  (6,646)
  18. Obesity  (6,150)
  19. More options open sub menu

Language 

  1. English  (28,927)
  2. Japanese  (2,459)
  3. Portuguese  (73)
  4. German  (49)
  5. Spanish  (43)
  6. Norwegian  (41)
  7. French  (23)
  8. Chinese  (10)
  9. Turkish  (6)
  10. Italian  (5)
  11. Persian  (4)
  12. Polish  (3)
  13. Russian  (2)
  14. Welsh  (1)
  15. Korean  (1)
  16. Kinyarwanda  (1)
  17. More options open sub menu

Searching Remote Databases, Please Wait